Global Alcoholic Hepatitis Therapeutic

Alcoholic Hepatitis Therapeutic Comprehensive Study by Type (Monoclonal Antibodies, Caspase Protease Inhibitor, Corticosteroids, Hemorheologic Agents, Anabolic Steroids, Hepatotropic Hormones, Sulfhydryl Agents, Others), Application (Hospitals and Clinics, Research and Development) Players and Region - Global Market Outlook to 2030

Alcoholic Hepatitis Therapeutic Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Alcoholic Hepatitis Therapeutic Market Scope
Alcoholic hepatitis disease is a leading cause of liver-related mortality and morbidity across the world. Increasing incidence of liver diseases and high success rate of pipeline drugs are the major factors which increase global alcoholic hepatitis market. Furthermore, surged focus on retaining the best quality of life is one the factor contributing to the growth of the market.



Alcoholic Hepatitis Therapeutic is a fragmented market with the presence of a number of players. The players are focusing on the new launch, merger, acquisition, investment, funding, and other activities. These activities help them to sustain in the market and enhance their market presence over the globe. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Alcoholic Hepatitis Therapeutic market throughout the predicted period.

Alkermes Inc. (Ireland), Conatus pharmaceuticals (United States), Dainippon sumitomo pharma (Japan), Teva Pharmaceuticals (Israel), Sanofi-Aventis (France), Generon (Shanghai) Corporation Ltd. (China), Immuron limited (Australia) and Lupin Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Intercept Pharmaceuticals (United States) and Alfact Innovation (France).

Segmentation Overview
The study have segmented the market of Global Alcoholic Hepatitis Therapeutic market by Type (Monoclonal Antibodies, Caspase Protease Inhibitor, Corticosteroids, Hemorheologic Agents, Anabolic Steroids, Hepatotropic Hormones, Sulfhydryl Agents and Others), by Application (Hospitals and Clinics and Research and Development) and Region with country level break-up.

On the basis of geography, the market of Alcoholic Hepatitis Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Rising Disposable Income among the Population and High Adoption Rate for Novel Therapeutics for Liver Diseases and High Adoption Rate for Novel Therapeutic Products

Market Growth Drivers:
Increasing Incidence of Liver Diseases and High Success Rate of Pipeline Drugs and Rising Disposable Income among the Population in both Developing and Developed Nations

Challenges:
High Development Cost and Dearth of Skilled Professionals

Restraints:
Increasing Health Care Expenditure and Stringent Reimbursement Policies

Opportunities:
Increasing Merger and Acquisitions among Pharmaceutical Companies to Develop Advance Therapies for Treating Liver Diseases

In 2020, DURECT Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DUR-928 for the treatment of alcoholic hepatitis. In order to speed up the research and review of medicines that have the potential to treat serious conditions where there is a medical need, the FDA provides Fast Track Designation.


Key Target Audience
Alcoholic Hepatitis Therapeutic Providers, Pharmaceutical Companies, Government Regulatory Bodies, End Users and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Caspase Protease Inhibitor
  • Corticosteroids
  • Hemorheologic Agents
  • Anabolic Steroids
  • Hepatotropic Hormones
  • Sulfhydryl Agents
  • Others
By Application
  • Hospitals and Clinics
  • Research and Development
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Liver Diseases and High Success Rate of Pipeline Drugs
      • 3.2.2. Rising Disposable Income among the Population in both Developing and Developed Nations
    • 3.3. Market Challenges
      • 3.3.1. High Development Cost
      • 3.3.2. Dearth of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Rising Disposable Income among the Population and High Adoption Rate for Novel Therapeutics for Liver Diseases
      • 3.4.2. High Adoption Rate for Novel Therapeutic Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Alcoholic Hepatitis Therapeutic, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Alcoholic Hepatitis Therapeutic (Value)
      • 5.2.1. Global Alcoholic Hepatitis Therapeutic by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Caspase Protease Inhibitor
        • 5.2.1.3. Corticosteroids
        • 5.2.1.4. Hemorheologic Agents
        • 5.2.1.5. Anabolic Steroids
        • 5.2.1.6. Hepatotropic Hormones
        • 5.2.1.7. Sulfhydryl Agents
        • 5.2.1.8. Others
      • 5.2.2. Global Alcoholic Hepatitis Therapeutic by: Application (Value)
        • 5.2.2.1. Hospitals and Clinics
        • 5.2.2.2. Research and Development
      • 5.2.3. Global Alcoholic Hepatitis Therapeutic Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Alcoholic Hepatitis Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alkermes Inc. (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Conatus pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dainippon sumitomo pharma (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceuticals (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi-Aventis (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Generon (Shanghai) Corporation Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Immuron limited (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lupin Laboratories (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Alcoholic Hepatitis Therapeutic Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Alcoholic Hepatitis Therapeutic (Value)
      • 7.2.1. Global Alcoholic Hepatitis Therapeutic by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Caspase Protease Inhibitor
        • 7.2.1.3. Corticosteroids
        • 7.2.1.4. Hemorheologic Agents
        • 7.2.1.5. Anabolic Steroids
        • 7.2.1.6. Hepatotropic Hormones
        • 7.2.1.7. Sulfhydryl Agents
        • 7.2.1.8. Others
      • 7.2.2. Global Alcoholic Hepatitis Therapeutic by: Application (Value)
        • 7.2.2.1. Hospitals and Clinics
        • 7.2.2.2. Research and Development
      • 7.2.3. Global Alcoholic Hepatitis Therapeutic Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Alcoholic Hepatitis Therapeutic: by Type(USD Million)
  • Table 2. Alcoholic Hepatitis Therapeutic Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 3. Alcoholic Hepatitis Therapeutic Caspase Protease Inhibitor , by Region USD Million (2018-2023)
  • Table 4. Alcoholic Hepatitis Therapeutic Corticosteroids , by Region USD Million (2018-2023)
  • Table 5. Alcoholic Hepatitis Therapeutic Hemorheologic Agents , by Region USD Million (2018-2023)
  • Table 6. Alcoholic Hepatitis Therapeutic Anabolic Steroids , by Region USD Million (2018-2023)
  • Table 7. Alcoholic Hepatitis Therapeutic Hepatotropic Hormones , by Region USD Million (2018-2023)
  • Table 8. Alcoholic Hepatitis Therapeutic Sulfhydryl Agents , by Region USD Million (2018-2023)
  • Table 9. Alcoholic Hepatitis Therapeutic Others , by Region USD Million (2018-2023)
  • Table 10. Alcoholic Hepatitis Therapeutic: by Application(USD Million)
  • Table 11. Alcoholic Hepatitis Therapeutic Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 12. Alcoholic Hepatitis Therapeutic Research and Development , by Region USD Million (2018-2023)
  • Table 13. South America Alcoholic Hepatitis Therapeutic, by Country USD Million (2018-2023)
  • Table 14. South America Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 15. South America Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 16. Brazil Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 17. Brazil Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 18. Argentina Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 19. Argentina Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 20. Rest of South America Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 21. Rest of South America Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 22. Asia Pacific Alcoholic Hepatitis Therapeutic, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 24. Asia Pacific Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 25. China Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 26. China Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 27. Japan Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 28. Japan Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 29. India Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 30. India Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 31. South Korea Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 32. South Korea Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 33. Taiwan Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 34. Taiwan Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 35. Australia Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 36. Australia Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 39. Europe Alcoholic Hepatitis Therapeutic, by Country USD Million (2018-2023)
  • Table 40. Europe Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 41. Europe Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 42. Germany Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 43. Germany Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 44. France Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 45. France Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 46. Italy Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 47. Italy Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 48. United Kingdom Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 49. United Kingdom Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 50. Netherlands Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 51. Netherlands Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 52. Rest of Europe Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 53. Rest of Europe Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 54. MEA Alcoholic Hepatitis Therapeutic, by Country USD Million (2018-2023)
  • Table 55. MEA Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 56. MEA Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 57. Middle East Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 58. Middle East Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 59. Africa Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 60. Africa Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 61. North America Alcoholic Hepatitis Therapeutic, by Country USD Million (2018-2023)
  • Table 62. North America Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 63. North America Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 64. United States Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 65. United States Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 66. Canada Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 67. Canada Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 68. Mexico Alcoholic Hepatitis Therapeutic, by Type USD Million (2018-2023)
  • Table 69. Mexico Alcoholic Hepatitis Therapeutic, by Application USD Million (2018-2023)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Alcoholic Hepatitis Therapeutic: by Type(USD Million)
  • Table 79. Alcoholic Hepatitis Therapeutic Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 80. Alcoholic Hepatitis Therapeutic Caspase Protease Inhibitor , by Region USD Million (2025-2030)
  • Table 81. Alcoholic Hepatitis Therapeutic Corticosteroids , by Region USD Million (2025-2030)
  • Table 82. Alcoholic Hepatitis Therapeutic Hemorheologic Agents , by Region USD Million (2025-2030)
  • Table 83. Alcoholic Hepatitis Therapeutic Anabolic Steroids , by Region USD Million (2025-2030)
  • Table 84. Alcoholic Hepatitis Therapeutic Hepatotropic Hormones , by Region USD Million (2025-2030)
  • Table 85. Alcoholic Hepatitis Therapeutic Sulfhydryl Agents , by Region USD Million (2025-2030)
  • Table 86. Alcoholic Hepatitis Therapeutic Others , by Region USD Million (2025-2030)
  • Table 87. Alcoholic Hepatitis Therapeutic: by Application(USD Million)
  • Table 88. Alcoholic Hepatitis Therapeutic Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 89. Alcoholic Hepatitis Therapeutic Research and Development , by Region USD Million (2025-2030)
  • Table 90. South America Alcoholic Hepatitis Therapeutic, by Country USD Million (2025-2030)
  • Table 91. South America Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 92. South America Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 93. Brazil Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 94. Brazil Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 95. Argentina Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 96. Argentina Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 97. Rest of South America Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 98. Rest of South America Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 99. Asia Pacific Alcoholic Hepatitis Therapeutic, by Country USD Million (2025-2030)
  • Table 100. Asia Pacific Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 101. Asia Pacific Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 102. China Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 103. China Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 104. Japan Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 105. Japan Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 106. India Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 107. India Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 108. South Korea Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 109. South Korea Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 110. Taiwan Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 111. Taiwan Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 112. Australia Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 113. Australia Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 114. Rest of Asia-Pacific Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 115. Rest of Asia-Pacific Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 116. Europe Alcoholic Hepatitis Therapeutic, by Country USD Million (2025-2030)
  • Table 117. Europe Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 118. Europe Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 119. Germany Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 120. Germany Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 121. France Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 122. France Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 123. Italy Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 124. Italy Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 125. United Kingdom Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 126. United Kingdom Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 127. Netherlands Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 128. Netherlands Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 129. Rest of Europe Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 130. Rest of Europe Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 131. MEA Alcoholic Hepatitis Therapeutic, by Country USD Million (2025-2030)
  • Table 132. MEA Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 133. MEA Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 134. Middle East Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 135. Middle East Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 136. Africa Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 137. Africa Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 138. North America Alcoholic Hepatitis Therapeutic, by Country USD Million (2025-2030)
  • Table 139. North America Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 140. North America Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 141. United States Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 142. United States Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 143. Canada Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 144. Canada Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 145. Mexico Alcoholic Hepatitis Therapeutic, by Type USD Million (2025-2030)
  • Table 146. Mexico Alcoholic Hepatitis Therapeutic, by Application USD Million (2025-2030)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Alcoholic Hepatitis Therapeutic: by Type USD Million (2018-2023)
  • Figure 5. Global Alcoholic Hepatitis Therapeutic: by Application USD Million (2018-2023)
  • Figure 6. South America Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 7. Asia Pacific Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 8. Europe Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 9. MEA Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 10. North America Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 11. Global Alcoholic Hepatitis Therapeutic share by Players 2023 (%)
  • Figure 12. Global Alcoholic Hepatitis Therapeutic share by Players (Top 3) 2023(%)
  • Figure 13. Global Alcoholic Hepatitis Therapeutic share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Alkermes Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 16. Alkermes Inc. (Ireland) Revenue: by Geography 2023
  • Figure 17. Conatus pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Conatus pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 19. Dainippon sumitomo pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Dainippon sumitomo pharma (Japan) Revenue: by Geography 2023
  • Figure 21. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 23. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi-Aventis (France) Revenue: by Geography 2023
  • Figure 25. Generon (Shanghai) Corporation Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 26. Generon (Shanghai) Corporation Ltd. (China) Revenue: by Geography 2023
  • Figure 27. Immuron limited (Australia) Revenue, Net Income and Gross profit
  • Figure 28. Immuron limited (Australia) Revenue: by Geography 2023
  • Figure 29. Lupin Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 30. Lupin Laboratories (India) Revenue: by Geography 2023
  • Figure 31. Global Alcoholic Hepatitis Therapeutic: by Type USD Million (2025-2030)
  • Figure 32. Global Alcoholic Hepatitis Therapeutic: by Application USD Million (2025-2030)
  • Figure 33. South America Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 34. Asia Pacific Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 35. Europe Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 36. MEA Alcoholic Hepatitis Therapeutic Share (%), by Country
  • Figure 37. North America Alcoholic Hepatitis Therapeutic Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alkermes Inc. (Ireland)
  • Conatus pharmaceuticals (United States)
  • Dainippon sumitomo pharma (Japan)
  • Teva Pharmaceuticals (Israel)
  • Sanofi-Aventis (France)
  • Generon (Shanghai) Corporation Ltd. (China)
  • Immuron limited (Australia)
  • Lupin Laboratories (India)
Additional players considered in the study are as follows:
Intercept Pharmaceuticals (United States) , Alfact Innovation (France)
Select User Access Type

Key Highlights of Report


Mar 2024 169 Pages 93 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Alcoholic Hepatitis Therapeutic Quantitative research analysis
Global Alcoholic Hepatitis Therapeutic Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Alcoholic Hepatitis Therapeutic study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Alcoholic Hepatitis Therapeutic Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Alcoholic Hepatitis Therapeutic market is expected to see growth rate of xx%.
The Alcoholic Hepatitis Therapeutic market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Alcoholic Hepatitis Therapeutic Report?

Have a Query? Click Here

Other Related Reports

Drug Addiction Treatment Comprehensive Study by Type (Methadone, Buprenorphine, Naltrexone, Bupropion, Varenicline, Others), Application (Hospitals, Clinics), Addiction Type (Opioid Addiction, Tobacc...
$ 3750
Allergy Skin Test Comprehensive Study by Type (Scratch, Intradermal, Patch), Application (Hospitals And Clinics, Diagnostics Centers), Indication (Allergic Rhinitis, Allergic Asthma, Drug Allergy, Fo...
$ 3500
Ambulatory EHR Comprehensive Study by Application (Practice Management, Patient Management, E-Prescribing, Referral Management, Population Health Management, Decision Support, Health Analytics), Depl...
$ 3750
Diabetes Treatment Comprehensive Study by Diabetes Type (Type 1 Diabetes, Type 2 Diabetes), Device Type (Blood Glucose Monitoring Device (Testing Strips, Self-monitoring Blood Glucose Meters, Lancets...
$ 3750
Medical Device Cleaning Services Comprehensive Study by Type (Manual Cleaning, Automatic Cleaning), Application (Hospitals, Clinics, Diagnostic Centers, Other), Process (Cleaning, Disinfecting, Steri...
$ 3500
Wound Irrigation Solution Comprehensive Study by Type (Wetting Agents, Antiseptics, Others), Distribution Channel (Online, Offline), End User (Hospitals, Ambulatory Surgical Centers, Clinics, Long Te...
$ 3350